BCAX (Bicara Therapeutics Inc. Common Stock) Stock Analysis - News
Bicara Therapeutics Inc. Common Stock (BCAX) is a publicly traded Healthcare sector company. As of May 21, 2026, BCAX trades at $20.43 with a market cap of $1.27B and a P/E ratio of -8.10. BCAX moved +2.05% today. Year to date, BCAX is +26.82%; over the trailing twelve months it is +35.84%. Its 52-week range spans $7.80 to $28.09. Analyst consensus is strong buy with an average price target of $30.99. Rallies surfaces BCAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in BCAX news today?
Bicara posts $8.3M Q1 net loss, advances BT-11 Phase 1b/2a and BT-12 IND: Bicara Therapeutics posted a Q1 net loss of $8.3 million, R&D spending of $5.1 million and SG&A expenses of $3.2 million, leaving $62.5 million in cash at March 31. The company advanced BT-11 into Phase 1b/2a atopic dermatitis trials and filed an IND for BT-12 psoriasis.
Bicara posts $8.3M Q1 net loss, advances BT-11 Phase 1b/2a and BT-12 IND: Bicara Therapeutics posted a Q1 net loss of $8.3 million, R&D spending of $5.1 million and SG&A expenses of $3.2 million, leaving $62.5 million in cash at March 31. The company advanced BT-11 into Phase 1b/2a atopic dermatitis trials and filed an IND for BT-12 psoriasis.
Does Rallies summarize BCAX news?
Yes. Rallies summarizes BCAX news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is BCAX research on Rallies investment advice?
No. Rallies provides research, data, and educational context for BCAX. It does not provide personalized investment advice.
